论文部分内容阅读
为探讨肝细胞癌（HCC）患者的性激素水平及其可能所起的作用，我们对64例男性肝病患者和正常男性对照20人的血清睾酮（T）、雄烯二酮（△4－A）、雌二醇（E2）、促卵泡生成素（FSH）和黄体生成素（LH）进行了检测。其中，HCC伴肝硬化（LC）患者15人；HCC不伴LC患者9人；LC患者30人；继发性肝肿瘤患者10人。结果显示：各组原发性肝病患者的血清T水平均低于正常（P＜0．01），而继发性肝肿瘤患者则正常；LC组患者的血清E2较正常水平显著增高（P＜0．01），LC伴HCC组患者与正常组E2水平增高（P＜0．05），HCC不件LC组、继发性肝肿瘤组患者与正常人相比E2无明显变化。结果表明：低水平T与原发性肝细胞癌（PMQ有关，在PHC的发生和发展中可能起一定的作用。
To investigate the level of sex hormone in patients with hepatocellular carcinoma (HCC) and its possible role, we measured serum testosterone (T), androstenedione (△ 4-A) in 64 male patients with liver disease and 20 normal controls. , Estradiol (E2), follicle stimulating hormone (FSH) and luteinizing hormone (LH) were detected. Among them, HCC patients with cirrhosis (LC) 15; HCC without LC patients 9; LC patients 30; 10 patients with secondary liver cancer. The results showed that serum T level in patients with primary liver disease was lower than normal (P <0.01), while patients with secondary liver cancer were normal; serum E2 in patients with LC was significantly higher than normal (P < 0.01). The levels of E2 in LC patients with HCC and normal controls were significantly higher than those in normal controls (P <0.05). There was no significant difference in E2 between HCC patients with LC and those with secondary liver cancer. The results showed that low level of T is associated with primary hepatocellular carcinoma (PMQ) and may play a role in the development of PHC.